TITLE

Clot-busters war: Science by press release

AUTHOR(S)
Levin, Arthur A.
PUB. DATE
June 1993
SOURCE
HealthFacts;Jun93, Vol. 18 Issue 169, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on the contradictory results of published studies regarding the efficacy and safety of the clot-dissolving drug t-PA over its cheaper rival streptokinase. Public relations hype versus objective science; Genentech's claim on t-PA's efficacy; British epidemiologist Richard Peto's analysis of study results.
ACCESSION #
9307156817

Tags: DRUGS -- Testing

 

Related Articles

  • Drug testing. Taibbi, Robert // Current Health 2;Mar1993, Vol. 19 Issue 7, p22 

    Presents facts on drug testing. Urine sampling; Drug screening of employees, athletes and former drug addicts undergoing treatment; Blood testing for alcohol; Privacy versus protection.

  • Drugs studied in children.  // FDA Consumer;Mar1991, Vol. 25 Issue 2, p6 

    Lists various drugs that are currently undergoing Food and Drug Administration-sanctioned testing for use in children with AIDS and related disorders.

  • Anti-drug programs in the workplace: Are they here to stay? Hayghe, Howard V. // Monthly Labor Review;Apr91, Vol. 114 Issue 4, p26 

    Studies data on anti-drug programs in the workplace, compiled by the Bureau of Labor Statistics (BLS) in 1988 and 1990. How the Survey of Employer Anti-drug Programs was conducted; Drug-testing programs; Employee assistance programs; Establishment of formal written policies; Analysis of results.

  • Trials `a must' for disputed cholesterol drugs. Vines, G. // New Scientist;2/22/92, Vol. 133 Issue 1809, p11 

    Reports on the dispute in Great Britain over cholesterol-lowering drugs. The need for large trials of a new generation of these drugs, known as statins; The two sides of the dispute; Press reports that have led to fears of a consumer backlash against the drugs.

  • Benefits at odds with risks...  // New Scientist;3/21/92, Vol. 133 Issue 1813, p9 

    Discusses the row that has developed in Great Britain over the funding of the trial of the drug tamoxifen in about 15,000 healthy women by two big cancer charities. What the Medical Research Council is worried about; Possible side effects; Tamoxifen's manufacturer, ICI, believes risk is finely...

  • Charities angry at hitch in breast cancer trial. Brown, P. // New Scientist;3/21/92, Vol. 133 Issue 1813, p12 

    Reports on the row in Great Britain between the Medical Research Council and Britain's two biggest cancer charities over trials of a drug to prevent breast cancer. Why the MRC has withdrawn support of the trial; Response from the charities; The Department of Health does not have a view on the...

  • The European way.  // Drug Topics;5/6/96, Vol. 140 Issue 9, p34 

    Reports on efforts to make emulate the European Union's system of approving drugs.

  • The limited precision of phase I trials. Christian, Michaele C.; Korn, Edward L. // JNCI: Journal of the National Cancer Institute;11/16/94, Vol. 86 Issue 22, p1662 

    Editorial. Criticizes conventional phase I trial designs' tendency to give inappropriate dose recommendations. National Cancer Institute (NCI) Cancer Therapy Evaluation Program's commitment to exploring alternative phase I trial designs; Strategies for improving precision of estimating the...

  • Under the influence of poppy seeds.  // Tufts University Diet & Nutrition Letter;May92, Vol. 10 Issue 3, p2 

    Covers a report by James L. Abelson in the `Journal of the American Medical Association,' in which he states that a women was denied a job because urine samples tested positive for opiates after she had eaten a lemon poppy seed muffin. Effects of opiates; Amount of the drug found in poppy seed...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics